github link
Accession IconGSE99802

Fezakinumab (anti-IL-22) treatment in adults with moderate-to-severe atopic dermatitis

Organism Icon Homo sapiens
Sample Icon 301 Downloadable Samples
Technology Badge Icon Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description
We conducted a randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe AD unresponsive to conventional topical or systemic treatment. Fezakinumab (ILV-094; anti IL-22 monoclonal antibody) monotherapy was administered for 12 weeks (primary endpoint), and clinical responses were followed until week 20. AD transcriptome significantly improved at week 12 in fezakinumab vs. placebo (p<1E-18).
PubMed ID
Total Samples
302
Submitter’s Institution

Samples

Show of 0 Total Samples
Filter
Add/Remove
Accession Code
Title
Specimen part
Treatment
Subject
Processing Information
Additional Metadata
No rows found
Loading...